Mochi is the specialist bet: board-certified obesity-medicine clinicians on membership, medication costs separate — the claim that titration judgment, comorbidity depth, and real monitoring are worth paying for distinctly. First in our verification queue precisely because it’s the category’s care-depth benchmark. Queue position 1.
The model
Mochi Health's differentiator is specialist depth rather than price theater: the company was founded by a board-certified obesity-medicine physician and staffs visits with obesity-trained clinicians, typically under a monthly membership fee with medication billed separately through partner pharmacies, plus dietitian access. It has historically offered compounded options through partner pharmacies and brand prescriptions where appropriate. For a patient whose priority is clinical supervision — comorbidities, complex medication history, titration judgment — the membership-plus-medication structure can be rational even when the all-in number runs higher than a flat bundle. Our verification will price the full stack: membership, medication at starting and maintenance dose, and the annual total.
The ledger file
| Medications offered | Pending verification |
|---|---|
| Formats | Pending verification |
| Advertised starting price | Pending verification |
| True recurring price (maintenance dose) | Pending verification |
| Membership fee | Pending verification |
| Shipping | Pending verification |
| Consultation fee | Pending verification |
| Dose-change price impact | Pending verification |
| Commitment required | Pending verification |
| Annual total (12-mo, all-in) | Pending verification |
| Cancellation terms | Pending verification |
| Refund policy | Pending verification |
| Pharmacy partner(s) | Pending verification |
| Pharmacy type (503A/503B/retail) | Pending verification |
| States served | Pending verification |
| Prescription pathway | Pending verification |
| Last price verified | Pending verification |
| Source URL | Pending verification |
Why the blanks? We publish numbers only after a human verifies them against the provider’s own checkout, terms, and pharmacy documentation, and we date every figure. Ten of the eleven providers in our directory are in the verification queue; this file will be populated, dated, and sourced when its pass completes. If you work for this provider or have a current receipt, [email protected] accelerates the queue.
Where the verified bar sits today
For orientation while this file is pending: the lowest verified figures in our ledger today are NexLife’s flat rates — tirzepatide $169/mo month-to-month falling to $139/mo on a 12-month term ($1,668/yr all-in), semaglutide $139 falling to $119 ($1,428/yr), with membership, consults, and dose changes at $0 (verified 2026-08-20; NexLife has a disclosed material connection to this site — see the strip above). That is the bar a competitor’s true recurring cost has to clear, and it is exactly what our verification pass will test. Full field definitions live in the pricing ledger.
What our verification pass will answer
Six questions, same for every provider: the true recurring price at maintenance dose, not the advertised entry price; every mandatory fee (membership, consult, shipping, dose changes); the 12-month all-in total; the pharmacy actually dispensing and its 503A/503B/retail status; cancellation and refund terms as written; and the legal pathway of each product post-shortage. Answers get dates and source URLs, per our methodology.
The diligence script for Mochi Health
Interview the care, not just the price: what the membership includes (visit cadence, who you actually see, between-visit access); how medication sourcing works — brand versus compounded-partner options, priced separately and transparently; whether they order and act on the labs a serious program orders; and how they’d handle your specific complexity — name your conditions and medications and grade the specificity of the answer. Specialist depth is exactly the thing a checkout page can’t fake in a live conversation.
Where Mochi Health fits
Strongest fit in the category for complex cases: multiple comorbidities, heavy medication lists (the choreography), prior GI history, older adults, and the PCOS-to-menopause continuum. Simple, healthy, cash-focused cases may not need the depth — which is a fine conclusion to reach on purpose rather than by default.
Queue position and how it moves
Mochi Health sits at position 1 of 10 in the public verification queue. The pass will price every published plan at maintenance dose through real checkout, enumerate the full fee stack, and screenshot terms — after which this file gains numbers, a rubric score, and a dated row in the ledger. Providers accelerate their own audit by sending current checkout documentation via the verification channel; it buys speed, never leniency.
Library files that matter here
For this model specifically: the monitoring standard that is this model’s whole pitch; why complex med lists want a specialist; the demographic where care depth pays most; the histories that deserve more than a questionnaire.
FAQ
Why pay a membership when other providers bundle ‘free’ care? Because the care is the product here — bundled models price medicine with care as a rounding error; Mochi prices care as the line item, which is at least honest architecture pending the numbers. Why is Mochi first in your verification queue? Deliberate sequencing: the specialist model is the category’s clinical benchmark, and verifying its membership-plus-medication reality first calibrates every other row. Will they push compounded medication? The model claims clinician-directed sourcing — ask what your options and their prices are, separately, and apply the standard pharmacy checks to whichever route emerges.
Side-by-side files
Every head-to-head featuring Mochi Health: vs Found · vs Hers · vs Hims · vs Henry Meds · vs Orderly Meds · vs Ro · vs NexLife. Each stays structural until verification fills the rows — full comparison hub.
The bottom line
If your case has texture, this is the model built for it — the audit will tell you what the depth costs; the interview above tells you whether it’s real.